Session » 3S115 ACR/ARHP Abstract: Pediatric Rheum (976–981)

Date: Sunday, October 21, 2018

Time: 4:30PM-6:00PM

Meeting: 2018 ACR/ARHP Annual Meeting

4:30PM-6:00PM: Abstract Number: 980

Long-Term Outcome of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis:Results of 18-Year Follow-up in the Population-Based Nordic JIA Cohort

4:30PM-6:00PM: Abstract Number: 981

New Consensus on an Updated Core Domain Set for Clinical Trials in Juvenile Idiopathic Arthritis

4:30PM-6:00PM: Abstract Number: 977

Nurse Led Safe Switching from Original Reference Product Infliximab to Biosimalar in Patients with Juvenile Idiopathic Arthritis and Uveitis – a Single Centre Experience Including Baseline and Post Switch Infliximab Levels and Antibodies

4:30PM-6:00PM: Abstract Number: 979

Stopping Medicines for Inactive Juvenile Idiopathic Arthritis: What Do Patients and Families Consider?

4:30PM-6:00PM: Abstract Number: 976

Transitioning from Paediatric to Adult Health Services: Development of an Integrated Programme Incorporating Patient and Provider Values

4:30PM-6:00PM: Abstract Number: 978

Treat-to-Target Study for Improved Outcome in Polyarticular Juvenile Idiopathic Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].